Compounds > nordamnacanthal
Page last updated: 2024-11-07

nordamnacanthal

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

nordamnacanthal: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID160712
CHEMBL ID2297225
SCHEMBL ID16227182
MeSH IDM0439061

Synonyms (9)

Synonym
2-anthracenecarboxaldehyde, 9,10-dihydro-1,3-dihydroxy-9,10-dioxo-
nordamnacanthal
3736-59-2
1,3-dihydroxy-9,10-dioxo-anthracene-2-carbaldehyde
ccris 6442
CHEMBL2297225
SCHEMBL16227182
DTXSID10190805
1,3-dihydroxy-9,10-dioxo-9,10-dihydroanthracene-2-carbaldehyde

Research Excerpts

Actions

ExcerptReferenceRelevance
"Nordamnacanthal managed to inhibit the growth and induce cell death in MDA-MB231 and MCF-7 cell lines in vitro and cease the tumor progression of 4T1 cells in vivo. "( Subchronic toxicity, immunoregulation and anti-breast tumor effect of Nordamnacantal, an anthraquinone extracted from the stems of Morinda citrifolia L.
Abu, N; Alitheen, NB; Ismail, NH; Mohamad, NE; Nordin, N; Rasol, NE; Romli, MF; Subramani, T; Yeap, SK; Zamberi, NR, 2018)		1.92

Treatment

ExcerptReferenceRelevance
"Treatment with nordamnacanthal was also able to increase tumor immunity as evidenced by the immunophenotyping of the spleen and YAC-1 cytotoxicity assays."( Subchronic toxicity, immunoregulation and anti-breast tumor effect of Nordamnacantal, an anthraquinone extracted from the stems of Morinda citrifolia L.
Abu, N; Alitheen, NB; Ismail, NH; Mohamad, NE; Nordin, N; Rasol, NE; Romli, MF; Subramani, T; Yeap, SK; Zamberi, NR, 2018)		0.82
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (7)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's3 (42.86)29.6817
2010's3 (42.86)24.3611
2020's1 (14.29)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 20.17

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index20.17 (24.57)
Research Supply Index2.08 (2.92)
Research Growth Index4.62 (4.65)
Search Engine Demand Index15.26 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (20.17)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other7 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
damnacanthal
damnacanthal: structure given in first source; isolated from the stem bark and roots of Morinda lucida; a selective inhibitor of p56(lck) tyrosine kinase activity		3.1950aldehyde;
monohydroxyanthraquinone
9,10-anthraquinone
9,10-anthraquinone : An anthraquinone that is anthracene in which positions 9 and 10 have been oxidised to carbonyls.		2.0410anthraquinone
1-hydroxyanthraquinone
[no description available]		2.0510monohydroxyanthraquinone
rubiadin 1-methyl ether
rubiadin 1-methyl ether: structure given in first source; isolated from the stem bark and roots of Morinda lucida		2.0410
rubiadin
rubiadin: highly genotoxic in Salmonella typhimurium. rubiadin : A dihydroxyanthraquinone that is anthracene-9,10-dione substituted by hydroxy groups at positions 1 and 3 and a methyl group at position 2. It has been isolated from Rubia yunnanensis.		2.0410dihydroxyanthraquinoneantibacterial agent;
antioxidant;
hepatoprotective agent;
plant metabolite
ConditionIndicatedRelationship StrengthStudiesTrials
Leukemia, Lymphoblastic, Acute, T Cell
[description not available]		02.4110
Leukemia, Lymphocytic, T Cell
[description not available]		02.4110
Necrosis
The death of cells in an organ or tissue due to disease, injury or failure of the blood supply.		02.4110
Leukemia, T-Cell
A malignant disease of the T-LYMPHOCYTES in the bone marrow, thymus, and/or blood.		02.4110
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
A leukemia/lymphoma found predominately in children and young adults and characterized LYMPHADENOPATHY and THYMUS GLAND involvement. It most frequently presents as a lymphoma, but a leukemic progression in the bone marrow is common.		02.4110
Carcinoma, Epidermoid
[description not available]		02.1510
Cancer of Mouth
[description not available]		02.1510
Carcinoma, Squamous Cell
A carcinoma derived from stratified SQUAMOUS EPITHELIAL CELLS. It may also occur in sites where glandular or columnar epithelium is normally present. (From Stedman, 25th ed)		02.1510
Mouth Neoplasms
Tumors or cancer of the MOUTH.		02.1510
Breast Cancer
[description not available]		02.1710
Breast Neoplasms
Tumors or cancer of the human BREAST.		02.1710